retatrutide ly3437943 clinical trial results New Phase 3 data just dropped 👀 Eli Lilly's reported average weight loss approaching 30%, with some patients achieving historically associated with bariatric surgery. A few important caveats Incretin triple agonist retatrutide (LY3437943)

Patients carrying specific genetic variants may require different dosing strategies or compound combinations to optimize weight loss outcomes

If you are currently taking a GLP-1 medication and anticipating surgical body contouring, schedule a consultation now even before your weight stabilizes

Attendees who joined this session learned how to identify and resolve clinical gaps in weight loss programs, outline cost-contained program designs, and understand AIs role in potential cost savings

Curr Diabetes Rep 7:340347

Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes